 Home > Biochemistry News > Biotechnology News > Pufang Biotech announced that it will showcase its new drug linker technology aimed at expanding the therapeutic window of antibody-conjugated drugs (ADC) at the 33rd International Conference on Molecular Targets and Cancer Therapy

Pufang Biotech announced that it will showcase its new drug linker technology aimed at expanding the therapeutic window of antibody-conjugated drugs (ADC) at the 33rd International Conference on Molecular Targets and Cancer Therapy

 Last Update: 2021-11-05
 Source: Internet
 Author: User

Tags

physical properties fluorine

3 chemical properties

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Woodinville, Washington, U.
S.
, and Suzhou, China, October 8, 2021/PRNewswire/ - Pufang Bio-Bio announced today that it will conduct research and treatment in the American Association for Cancer Research (AACR), National Cancer Institute (NCI) and European Cancer Research and Treatment The 33rd International Conference on Molecular Targets and Cancer Therapeutics hosted by EORTC (AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics) presented the technical data of its new ADC linker platform in the form of a virtual poster.
The title of the poster For "the new hydrophilic drug linker gives exotecan-based ADC drugs better physicochemical properties and in vivo activity"
.

"Our platform technology can make ADC drugs that could not be developed otherwise
.

By optimizing the physical and chemical properties of the linker, our platform technology can achieve the payload ratio (DAR value) of a variety of hydrophobic drugs on the antibody to 8 or even It may be higher, and at the same time it keeps ADC close to naked anti-pharmacokinetics, strong and effective anti-tumor activity and acceptable safety

About Pufang Bio

Pufang Bio is a company focused on the development of a new generation of macromolecular targeted drugs.
Its product pipeline mainly includes antibody-conjugated drugs (ADC) and other antibody-based therapeutic solutions
.

Based on the innovative technology platform, Pufang Bio has developed a series of product pipelines composed of drug candidates targeting solid tumor targets.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.